Investors
Invest in InDex
Pharmaceuticals
-
InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis
November 24, 2021 Regulatory
-
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2021
November 24, 2021 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q3 for January-September 2021 on November 24, 2021 at 08:00 a.m. CET.
-
Year-end Report 2021
-
Annual Report 2021
-
Interim Report Q1 2022
InDex Pharmaceuticals in numbers
-
15-30
The most common age of an ulcerative colitis diagnosis
-
2 Million
Patients living with ulcerative colitis in the US and Europe
-
6.3 billion USD
Total yearly sales of medications for ulcerative colitis
-
8 billion USD
The estimated total yearly sales of medication for ulcerative colitis in 2023
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis.
Investor contact
